Presentation Authors: Hisanori Taniguchi*, Shigenari Kawakita, Hidefumi Kinoshita, Takashi Murota, Tadashi Matsuda, Hirakata, Japan
Introduction: Serum total testosterone profiles after treatment of radiation therapy (RT) for prostate cancer has not been clearly understood. This study was undertaken to evaluate the serum total testosterone level (STL) after brachytherapy (BT).
Methods: One hundred two men who underwent permanent interstitial BT using I125 without androgen deprivation therapy (ADT) for localized prostate cancer. Radiation dose for BT was seed 145 Gy. Patients followed at least 24 months up to 60 months after BT. Primary outcomes were STL after BT. Predictors of testosterone decrease were also analyzed.
Results: Median pre-implant STL was 4.18 ng/mL. STL had decreased significantly to a median nadir of 89.4% of baseline (3.72 ng/mL) occurring at 6 months and then recovered to baseline at 18 months after BT. Patients with lower median baseline STL (3.54 ng/mL) group tended to decrease below 3.00 ng/mL; those with higher median baseline STL (5.05 ng/mL) group tended to decrease by at least 1.00 ng/mL after treatment.
Conclusions: This present study revealed that although STL decreased significantly after I125 BT, the effect for STL decline after treatment for localized prostate cancer was not large and recovered over time.